Literature DB >> 11531284

Profiling of protein kinases in the neoplastic transformation of human ovarian surface epithelium.

A S Wong1, S O Kim, P C Leung, N Auersperg, S L Pelech.   

Abstract

OBJECTIVE: The aim of this study was to study the pattern of protein kinase expression in a culture model of epithelial ovarian carcinogenesis.
METHODS: Cultures of normal human ovarian surface epithelium (OSE), OSE from women with BRCA1 mutations, a cell culture model of preneoplastic (SV40 T-antigen-immortalized, nontumorigenic) and neoplastic (SV40-E-cadherin transfected, tumorigenic) OSE, and three ovarian cancer cell lines were used to represent OSE phenotypes of different genetic backgrounds and at different, progressive stages of neoplastic transformation. The protein kinase network signaling was studied by Western blotting, simultaneously using multiple antibodies for specific protein kinases.
RESULTS: High levels of cGMP-dependent protein kinase were found in normal and preneoplastic OSE, but were absent in neoplastic OSE. In contrast, expression of MEK6 was detected exclusively in neoplastic OSE. The expressions of casein kinase II (CK2), p38 mitogen-activated protein kinase (MAPK), cyclin-dependent kinase, and the phosphatidylinositol 3-kinase (PI3K) effectors Akt2 and p70 S6 kinase (S6K) were several-fold higher in neoplastic OSE than in normal OSE, whereas the expressions of the MAPKs extracellular signal-regulated kinases ERK1 and -2 were unchanged. Importantly, constitutive phosphorylation of Akt2 and p70 S6K, as found in neoplastic OSE, was also observed in overtly normal OSE from women with predisposing BRCA1 gene mutations.
CONCLUSIONS: These data demonstrate that different repertoires of downstream signaling proteins, particularly those of the MEK6-p38 MAPK-CK2 pathway and the PI3K pathway, are correlated with phenotypic manifestations of a cell culture model of OSE at progressive stages in the development of ovarian cancer. Changes in PI3K effectors are already found in overtly normal OSE from women with BRCA1 mutations. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11531284     DOI: 10.1006/gyno.2001.6280

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  14 in total

1.  Oncolytic virotherapy for ovarian cancer.

Authors:  Shoudong Li; Jessica Tong; Masmudur M Rahman; Trevor G Shepherd; Grant McFadden
Journal:  Oncolytic Virother       Date:  2012-08

Review 2.  Mammalian target of rapamycin: a central node of complex signaling cascades.

Authors:  Yoh Dobashi; Yasutaka Watanabe; Chihiro Miwa; Sakae Suzuki; Shinichiro Koyama
Journal:  Int J Clin Exp Pathol       Date:  2011-06-14

3.  Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo.

Authors:  Fiona Simpkins; Pedro Hevia-Paez; Jun Sun; Wendy Ullmer; Candace A Gilbert; Thiago da Silva; Ali Pedram; Ellis R Levin; Isildinha M Reis; Brian Rabinovich; Diana Azzam; Xiang-Xi Xu; Tan A Ince; Ji-Yeon Yang; Roel G W Verhaak; Yiling Lu; Gordon B Mills; Joyce M Slingerland
Journal:  Clin Cancer Res       Date:  2012-08-15       Impact factor: 12.531

Review 4.  Protein kinase CK2 in health and disease: CK2: a key player in cancer biology.

Authors:  J H Trembley; G Wang; G Unger; J Slaton; K Ahmed
Journal:  Cell Mol Life Sci       Date:  2009-06       Impact factor: 9.261

Review 5.  Protein kinase CK2: a potential therapeutic target for diverse human diseases.

Authors:  Christian Borgo; Claudio D'Amore; Stefania Sarno; Mauro Salvi; Maria Ruzzene
Journal:  Signal Transduct Target Ther       Date:  2021-05-17

6.  Human iPSC-derived fallopian tube organoids with BRCA1 mutation recapitulate early-stage carcinogenesis.

Authors:  Nur Yucer; Rodney Ahdoot; Michael J Workman; Alexander H Laperle; Maria S Recouvreux; Kathleen Kurowski; Diana J Naboulsi; Victoria Liang; Ying Qu; Jasmine T Plummer; Simon A Gayther; Sandra Orsulic; Beth Y Karlan; Clive N Svendsen
Journal:  Cell Rep       Date:  2021-12-28       Impact factor: 9.423

7.  MET/HGF Signaling Pathway in Ovarian Carcinoma: Clinical Implications and Future Direction.

Authors:  Paulette Mhawech-Fauceglia; Michelle Afkhami; Tanja Pejovic
Journal:  Patholog Res Int       Date:  2012-12-25

Review 8.  Ovarian surface epithelium: family history and early events in ovarian cancer.

Authors:  Alice S T Wong; Nelly Auersperg
Journal:  Reprod Biol Endocrinol       Date:  2003-10-07       Impact factor: 5.211

Review 9.  Mitogen-activated protein kinases in normal and (pre)neoplastic ovarian surface epithelium.

Authors:  Kyung-Chul Choi; Nelly Auersperg; Peter C K Leung
Journal:  Reprod Biol Endocrinol       Date:  2003-10-07       Impact factor: 5.211

10.  A Synthetic Lethality Screen Using a Focused siRNA Library to Identify Sensitizers to Dasatinib Therapy for the Treatment of Epithelial Ovarian Cancer.

Authors:  Harsh B Pathak; Yan Zhou; Geetika Sethi; Jeff Hirst; Russell J Schilder; Erica A Golemis; Andrew K Godwin
Journal:  PLoS One       Date:  2015-12-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.